Feasibility Trial Using an Inpatient Insulin Dosing Calculator
Part of paid clinical trials in Seattle, Washington.
- Sponsor
- University of Washington
- Study ID
- NCT06206525
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Initial insulin dosing calculator — OTHERParticipants received initial insulin doses by the calculator on hospital admission.
Study Details
The goal of this feasibility trial is to test whether a novel insulin dosing calculator can improve blood glucose management for patients with type 2 diabetes mellitus on hospital admission. The main questions it aims to answer are: * Whether using this calculator leads to no excessive hypoglycemia? * Whether using this calculator leads to a decrease of hyperglycemia? Participants will receive initial insulin doses by the calculator on hospital admission, and the rest of care will follow standard of care. Participants will be compared with patients in the UW observational cohort who received initial insulin doses by standard of care.
Key Dates
- Start date
- Mar 22, 2024
- Status verified
- Apr 2026
- Primary completion
- May 31, 2025
- Completion
- May 31, 2025
Study Design
- Enrollment
- 38 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Initial insulin dosing calculator
- No Intervention: Observational cohortHistorical patients who received initial insulin doses by standard of care
Primary Outcome Measure
Clinical Significant Hypoglycemia [ Time Frame: During the first 48 hours after admission ]
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Harborview Medical Center | Seattle | Washington | 98104 | - |
| UW Medical Center - Montlake | Seattle | Washington | 98195 | - |
| UW Medical Center - Northwest | Seattle | Washington | 98133 | - |
Find similar trials in Seattle, WA
Related Studies
- Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 DiabetesPHASE4 · Recruiting · University of Washington · Seattle, Washington
- A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular EventsRecruiting · Cleerly, Inc. · Chandler, Arizona
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseasePHASE3 · Recruiting · Boehringer Ingelheim · Anniston, Alabama
- A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesPHASE2 · Recruiting · Eli Lilly and Company · Gilbert, Arizona